ClinicalTrials.gg
Status unknownNCT01321489Updated Mar 23, 2011

A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies

A Phase 3 interventional study of Sildenafil Citrate 20mg Tablet Sublingual and Viagra ® 50mg tablet Coated in Erectile Dysfunction, sponsored by Laboratório Teuto Brasileiro S/A. Status unknown at 1 site in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-23.

Sponsored by Laboratório Teuto Brasileiro S/A · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2011), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Planned enrollment
30th of 50
78 · median 108
Started
2011
with 4 others
Phase 3
6 of 50
1 open now
Registered
36th of 50
by date

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 30th largest by planned enrollment, is one of 5 that started in 2011, is one of 6 in phase 3, and was the 36th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability and safety of Sildenafil Citrate 20mg Sublingual tablet, as well as a possible superiority expressed by the faster onset of action compared to Viagra ® 50mg tablet Coated in erectile dysfunction.

Read the detailed description

Phase III clinical trial, comparative, open, multicenter, prospectively, with random inflow of 78 patients evaluable male patients with erectile dysfunction with IIEF-5 score in between 13 and 24, corresponding to mild or mild to moderate to evaluate the efficacy and safety as well as a possible superiority expressed by the faster onset of action onset of action of study medication.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Phase III
  • Sildenafil Citrate Tablet Sublingual
  • Erectile dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years;
  • Patients with erectile dysfunction of various etiologies (organic, psychogenic and mixed) for at least 6 months;
  • Patients with scores in the IIEF-5 between 13 and 24, which correspond to mild or mild to moderate;
  • Relationship stable for at least 6 months;
  • Patients should be kept with libido;
  • Education at least 4 years;
  • Do not use sildenafil, vardenafil, tadalafil, lodenafil, injection therapy or vacuum devices up to 72 hours before the screening visit;
  • Functions hepatic, hematological, hormonal and renal within the following benchmarks:
  • Creatinine: 0.6 to 1.10 mg / dl;
  • Urea: 10 - 50mg/dl;
  • TGP: up to 40 U / L;
  • TGO: ≤ 34 U / L;
  • Prolactin: 2.3 to 11.5 ng / ml Men
  • Total Testosterone: 241 to 827 ng/100 ml - Men
  • Blood glucose: 70 mg / dl and 99mg/dl.

Exclusion criteria

Exclusion Criteria:

  • Patients who have failed treatment with inhibitors of phospho-diesterase inhibitors;
  • Patients undergoing radical prostatectomy;
  • Patients with to any component of the formula;
  • Presence of genital deformities or other disorders that prevent intercourse;
  • Operations prior to penile erectile dysfunction or premature ejaculation penis enlargement;
  • Use of other treatments for erectile dysfunction or concomitant treatment with nitrates;
  • Myocardial infarction or cerebrovascular accident (CVA) for less than 6 months;
  • Heart disease or uncontrolled serious;
  • Injury cord injury;
  • Multiple sclerosis;
  • Retinitis pigmentosa;
  • Neoplasms known in business and / or treatment;
  • History of severe anaphylactic reactions and disease Steven-Johnson;
  • Participation in a clinical study in the 2 months prior to inclusion;
  • Patients who are making use of antiretrovirals;
  • Any other disease or condition is not matched that in the opinion of the investigator, could lead to increased risk for the patient or who makes it inappropriate for this study;
  • Comorbidities such as diabetes mellitus, malignant hypertension, blood pressure (BP), systolic> 170 mmHg, diastolic BP levels> 110 mmHg, blood pressure \<80 x 50 mmHg, significant cardiovascular disease, alcohol or drugs, or other disorders important.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Sildenafil Citrate 20mg Tablet Sublingual

    Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

    Drug: Viagra ® 50mg tablet Coated

  • Active comparator
    Viagra ® 50mg tablet Coated

    Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

    Drug: Sildenafil Citrate 20mg Tablet Sublingual

Interventions

  • Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

  • Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

06

What researchers measure

Primary outcomes

  1. Evaluate a possible superiority expressed by the faster onset of action.

    To evaluate a possible superiority expressed by the faster onset of action of Sildenafil Citrate 20mg Tablet Sublingual compared to Viagra ® 50mg tablet Coated in erectile dysfunction.

    Time frame: 35 days

Secondary outcomes

  1. Evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in control of Erectile Dysfunction.

    The secondary outcame measure will be to evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in patients with Erectile Dysfunction.

    Time frame: 35 days

07

Study locations

1 site
  • Ipiranga Hospital
    Sao Paulo, 04262-000, Brazil
    • Sidney Glina, Investigator · Contacturohi@uol.com.br · 55 (11) 2069-9629
    • Bluette Sandila, Coordenator · Contactbluette.urohi@uol.com.br · 55 (11) 2069-9629
    • Sidney Glina, Investigator · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2011
First posted
Mar 23, 2011
Start
Sep 2011
Primary completionEst.
Jan 2012
CompletionEst.
Jan 2012
Last update
Mar 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01321489
Lead sponsor
Laboratório Teuto Brasileiro S/A
First posted
Mar 23, 2011
Start date
Sep 2011
Primary completion
Jan 2012 (estimated)
Completion
Jan 2012 (estimated)
Last update
Mar 23, 2011

Study contacts

Sidney Glina, Investigator
Contact
urohi@uol.com.br
55 (11) 2069-9629
Bluette Sandila, Coordenator
Contact
bluette.urohi@uol.com.br
55 (11) 2069-9629
Eduardo Bertero, Investigator
principal investigator · Hospital for State Civil Servants of Sao Paulo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion